Neurocrine appoints Kyle Gano as CEO effective Oct 11, 2024; base salary $900k

NEUROCRINE BIOSCIENCES INC

Kyle Gano, Ph.D. named President and CEO effective October 11, 2024, under an amended employment agreement.
Annual base salary of $900,000; target cash bonus of 100% of base salary.
Promotion equity grants: $750k stock options, $300k RSUs, $450k PRSUs (total $1.5M).
Severance includes 1.5x salary plus bonus for non-CIC termination; 2x for CIC termination with full vesting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kyle Gano

President and Chief Executive Officer

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2024-10-11
Filed: October 11, 2024, 7:59 PM ET

Pursuant to the Employment Agreement, Dr. Gano will serve as Neurocrine Biosciences’ President and Chief Executive Officer effective October 11, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kyle Gano was appointed as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Pursuant to the Employment Agreement, Dr. Gano will serve as Neurocrine Biosciences’ President and Chief Executive Officer effective October 11, 2024 (the “Effective Date”).

View on SEC.gov

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-24-000206

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.